Volatility can lower the cost of entry into businesses that throw off real cash, even as investors recognize that a low share ...

A comprehensive new review published in The Lancet affirms that currently approved mRNA vaccines are safe and highly ...

The mRNA vaccines approved to treat COVID-19 are safe and effective and show promise in treating other diseases including ...

A bipartisan group of U.S. lawmakers opened national security investigations into whether five drugmakers including Merck and ...

Lawmakers asked the drugmakers to provide details of due diligence, data protection processes and other standards at their ...

Final results from the CNS-101 study, published in Frontiers in Digital Health, show that the NeuLogiq Platform can be used ...

The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of ...

Proceeds will fund advancement of ARON degrader, FX-111, to proof of concept and preclinical development of ARON RIPTAC program- Veteran ...

Pharmaceutical companies are on an M&A spree that could break records this year as they look for novel drug and clinical-stage candidates to bolster the development pipeline.

CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds long-term potential ...

A research paper done by a Harvard professor showed the employment rate for women rose by 27% after taking GLP-1s.

The FAST study, officially titled “Evaluation of Function And Satisfaction of UbrogepanT-treated Migraine Patients in Canada,” looks at how well adults function and how satisfied they feel after using ...